Potential Risks GLP-1 medications have shown promise in reducing the severity of OSA through weight loss and related physiological changes
Kristina screens for contraindications, monitors weight, vitals, and labs as indicated, and adjusts your dose or pauses titration whenever needed to keep you both comfortable and safe
For most people, it is mild to moderate and tends to improve as the body adjusts over several weeks
The challenges encountered with behavioral interventions alone necessitate understanding why early pharmacological intervention may be warranted
Nutritional Support: Personalized supplementation for deficiencies (B vitamins, CoQ10, magnesium)
Tuttavia, lapprovazione europea non equivale alla commercializzazione immediata: in Italia necessario attendere la determinazione AIFA sulla classificazione e sul prezzo, un iter separato che tipicamente richiede diversi mesi